MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtcvs.2015.08.073

Медицинская библиотека · The Journal of thoracic and cardiovascular surgery · 2015

Periportal fibrosis without cirrhosis does not affect outcomes after continuous flow ventricular assist device implantation.

Sargent Jonathon E, Dardas Todd F, Smith Jason W, Pal Jay D, Cheng Richard K, Masri S Carolina, Shively Kent R, Colyer Lauren M, Mahr Claudius, Mokadam Nahush A

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

This study investigates the relationship of periportal fibrosis on postoperative outcomes after ventricular assist device (VAD) implantation.

METHODS

Between July 2005 and August 2014, a total of 233 patients were implanted with continuous flow VADs. Liver biopsy was performed on 16 patients with concern for liver disease. Survival was evaluated using the Kaplan-Meier method. The effect of fibrosis on length of stay (LOS) in the intensive care unit was modeled using Poisson regression. Adjustments were made for age, profile from the Interagency Registry for Mechanically Assisted Circulatory Support, biopsy, and model for end-stage liver disease score.

RESULTS

Fourteen of the 16 patients who underwent biopsy had periportal fibrosis without cirrhosis. One-year survival for the groups with and without biopsy-proven fibrosis was 93% ± 7% and 86% ± 2% (P = .97), respectively. The intensive care unit LOS was not different for those with (median, 7 days; interquartile range: 3-14 days) versus without fibrosis (median, 6 days; interquartile range 4-10 days; P = .65). Fibrosis (P = .42), age (0.95), model for end-stage liver disease excluding internal normalized ratio-XI score (P = .64), performance of a biopsy (P = .28), and Interagency Registry for Mechanically Assisted Circulatory Support class (P = .70) were not associated with intensive care unit LOS. Risk was increased of gastrointestinal bleeding (14% vs 4%; P = .026) in the first year among patients with fibrosis.

CONCLUSIONS

The presence of periportal fibrosis did not affect survival or outcomes in patients undergoing VAD implantation. These findings suggest that carefully selected patients with advanced heart failure and hepatic fibrosis without cirrhosis may achieve acceptable outcomes with VAD implantation.

Для цитирования: Sargent Jonathon E, Dardas Todd F, Smith Jason W, Pal Jay D, Cheng Richard K, Masri S Carolina, Shively Kent R, Colyer Lauren M, Mahr Claudius, Mokadam Nahush A. Periportal fibrosis without cirrhosis does not affect outcomes after continuous flow ventricular assist device implantation.. The Journal of thoracic and cardiovascular surgery. 2015. DOI: 10.1016/j.jtcvs.2015.08.073.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.